Udi Meirav - 26 Jul 2021 Form 3 Insider Report for Candel Therapeutics, Inc. (CADL)

Role
Director
Signature
/s/ Udi Meirav
Issuer symbol
CADL
Transactions as of
26 Jul 2021
Net transactions value
$0
Form type
3
Filing time
26 Jul 2021, 21:25:56 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CADL Common Stock 48,822 26 Jul 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CADL Stock Option (Right to Buy) 26 Jul 2021 Common Stock 12,205 $1.46 Direct F1
holding CADL Stock Option (Right to Buy) 26 Jul 2021 Common Stock 71,198 $1.46 Direct F2
holding CADL Stock Option (Right to Buy) 26 Jul 2021 Common Stock 16,274 $1.55 Direct F2
holding CADL Stock Option (Right to Buy) 26 Jul 2021 Common Stock 16,274 $6.64 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option vested and became exercisable on January 1, 2019, with the remainder vesting in three substantially equal monthly installments thereafter.
F2 This option is fully vested and exercisable as of the date hereof.